Immutep LtdASX: IMM

Immutep Expands US Patents for Efti Combination Therapies

· Issued by Immutep Ltd via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Immutep Ltd announced the grant of a new patent for Efti-based combination therapies by the United States Patent and Trademark Office. The CEO emphasized the importance of a strong patent portfolio for future development and partnership opportunities. Efti is a proprietary protein that activates immune responses and has received designations from the U.S. FDA for specific cancer treatments.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies SYDNEY, AUSTRALIA – 11 November 2026 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a...

Immutep Ltd on 6ix

Earlier from Immutep

Later from Immutep

All Immutep news releases